Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response’s anaphylaxis-related claims closely match the provided FDA label excerpts, including seriousness, timing, typical onset window, need for immediate (and usually permanent) discontinuation, contraindication in hypersensitivity to glatiramer acetate or mannitol, and overlap with immediate post-injection reactions. No contradictions or material omissions are evident from the provided label excerpts.
Category Scores
Accurate Statements
Life-threatening and fatal anaphylaxis has been reported with COPAXONE.
5.1: “Life-threatening and fatal anaphylaxis has been reported with COPAXONE.”
Anaphylaxis can occur any time after initiation (as early as after the first dose and up to years later).
5.1: “Anaphylaxis can occur at any time following initiation… from as early as after the first dose, up to years after initiation of treatment.”
In most reported cases, anaphylaxis occurred within an hour of a COPAXONE injection.
5.1: “Anaphylaxis occurred within an hour of a COPAXONE injection in most of the reported cases.”
If anaphylaxis occurs, treatment must be immediately discontinued; unless a clear alternative etiology is identified, COPAXONE must be permanently discontinued.
5.1: “If an anaphylactic reaction occurs, treatment with COPAXONE must be immediately discontinued… COPAXONE must be permanently discontinued.”
COPAXONE is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol, including reactions that have included anaphylaxis.
4: “COPAXONE is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol. Reactions have included anaphylaxis.”
Anaphylaxis signs/symptoms may overlap with immediate post-injection reaction symptoms.
5.2: “The symptoms of an immediate post-injection reaction may overlap with those of anaphylaxis; prompt identification of anaphylaxis is important…”
Unsupported Statements
Contradictions
Important Omissions
No discussion of immediate post-injection reactions prevalence by dose (e.g., ~16% for 20 mg/mL and ~2% for 40 mg/mL).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response accurately reflects the label’s anaphylaxis warning elements and contraindication; no unsupported or contradictory safety claims were identified based on the provided excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission of the label’s immediate post-injection reaction incidence figures by dose (not required for the core anaphylaxis warning accuracy).
Suggested Improvement
Optionally include the label’s approximate incidence rates for immediate post-injection reactions by dose if the response aims to be more comprehensive.